Leerink Partners Upgrades AN2 Therapeutics to Outperform, Announces $9 Price Target

Benzinga Newsdesk www.benzinga.com Positive 92.0%

Neg 0% Neu 0% Pos 92%

Leerink Partners analyst Joseph Schwartz upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Outperform and announces $9 price target.